Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cleveland Clinic Journal of Medicine (CCJM)
This six-chapter video series covers patient selection for neoadjuvant systemic treatment, adjuvant systemic treatment, neoadjuvant systemic treatment, post-neoadjuvant adjuvant treatment, survivorship and surveillance, and future directions.
Oncology, Medical July 11th 2022
Clinical Advances in Hematology & Oncology
Joyce A. O’Shaughnessy, MD provides updates on several key presentations from SABCS, touching on SERD therapy, ribociclib combinations, the datopotamab deruxtecan antibody-drug conjugate targeting overexpression of the calcium signal transducer TROP2, trastuzumab deruxtecan, and more. The MONALEESA phase 3 trial is looking at letrozole + ribociclib vs letrozole + placebo in postmenopausal women with ER+ HER2- advanced breast cancer. The trial arm outperformed the control arm with a median OS of 63.9 months vs 51.4 months respectively at a median follow up of just over 6.5 years. That median OS is the longest reported for any phase 3 trial in advanced breast cancer.
Oncology, Medical February 15th 2022
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS